Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

about

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

Item

http://www.wikidata.org/entity/Q54963955

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@en

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@nl

type

Item

label

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@en

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@nl

prefLabel

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@en

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@nl

P1476

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

@en

P2093

Dan Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaoxiao Yao

http://www.w3.org/2001/XMLSchema#string

Yien Xiang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Potentiality of immunotherapy against hepatocellular carcinoma

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells

Global cancer statistics, 2012

Smart CARs engineered for cancer immunotherapy

Mechanisms of type-I- and type-II-interferon-mediated signalling

Natural innate and adaptive immunity to cancer

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

P304

8740976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1155/2018/8740976

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

P5008

ScienceSource

P577

2018-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29785403

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

immunotherapy

liver neoplasm

liver cancer

hemic and immune systems

Achyolli

P932

5896259

http://www.w3.org/2001/XMLSchema#string